Top biopharma deal upfront November 2021

November 2021 Top Biopharma Deal: Sanofi – Owkin artificial intelligence and federated learning platform to advance Sanofi’s oncology pipeline

Dec 8, 2021 | Deal of the Month, Partnership Deals

November 2021 Top Biopharma Deal Upfront

Owkin discovery and development deal with Sanofi for AI models for cancer



Highlighted Deal Financial Comps

Date Announced:

November 18, 2021

Total Deal Value:

$270M + Mst

Upfront Cash:

$0 upfront, R&D funding $90M over 3 yrs

Upfront Equity:

$180M

Option Payments:

n/a

Total Milestones:

undisclosed R&D Mst

Royalties:

n/a

Cost & Profit Split:

n/a



Deal Synopsis

The Asset:

Owkin’s artificial intelligence and federated learning platform to support digital clinical research in Sanofi’s core oncology efforts in 4 different cancers.

Deal Structure:

R&D Only

Partnership Features:

Collaborative Development, Funded R&D

Deal Details:

Owkin will receive a $180M upfront equity investment, $90M in R&D funding over 3 years, and is eligible for additional undisclosed R&D milestones.
Sanofi will apply Owkin’s artificial intelligence (AI) and federated learning platform to advance its oncology pipeline, which includes non-small cell lung cancer (NSCLC), triple-negative breast cancer, mesothelioma, and multiple myeloma. This research partnership agreement will allow Sanofi to work closely with Owkin to identify new oncology treatments across 4 cancers.
Sanofi will use the Owkin platform to find new biomarkers and therapeutic targets, build prognostic models, and predict response to treatment from multimodal patient data.
Owkin’s global research network is powered by federated learning, which allows data scientists to securely connect to decentralized, multi-party data sets to train AI models without having to pool data. This approach will complement Sanofi’s developments oncology.

Last Month:

Congrats to Owkin and Sanofi for landing DealForma’s November 2021 Top Biopharma Deal. Last month’s Deal of the Month was Xencor – Janssen for Plamotamab and XmAb Bispecific Antibodies. Read about it here.

DealForma’s Deal of the Month selection is based on the largest disclosed upfront cash and equity total in partnership deals involving R&D as announced in the month prior to this article. Data for this analysis was compiled using the DealForma biopharma deals database. All data are based on publicly disclosed figures and deal terms.

We invite you to answer interesting questions on biopharma business development and licensing using our data and carefully curated profiles on deals, pipelines, companies, funding, and business executives by visiting dealforma.com to schedule your personalized demo.

21,598

Licensing Deals

22,217

Funding Rounds

4,216

M&A

35,278

Company Profiles

5,897

Other Deals

27,588

Drug Sales Figures

All of this by stage, disease indication, modality, target...

Schedule Your Demo

More Research by DealForma

Biopharma Venture Investment Through Q3 2023

Dec 1, 2023 | Analysis, Funding

Biopharma venture investment totals rebounded in Q3 2023, nearing 2020 quarterly levels. The number of rounds, especially for seed and Series A, are still depressed as we are seeing investors re-investing in later rounds of portfolio companies rather than new...

Biopharma M&A Through Q3 2023

Nov 22, 2023 | Analysis, M&A

This is a quick readout of biopharma M&A activity through Q3 2023 as we track the prominent deals for the year leading up to year-end. Among some of the largest in biopharma are Novo Nordisk's acquisition of Inversago Pharma offering shareholders up to $1.075...

Biopharma R&D Partnerships – Q3 2023 Review

Nov 17, 2023 | Analysis, Partnership Deals

Biotech, pharma, and medtech R&D partnerships in Q3 2023 settled to pre-2020 levels on total deal announced values but again on fewer deals. Major deal announcements in Q3 included Pfizer / Flagship Pioneering, Alnylam / Roche, Nanobiotix / Janssen, Orionis /...